Coverage
-
August 19, 2015
Specialty pharmaceutical company Acusphere Inc. fought back Tuesday against Celgene Corp.'s bid for attorneys' fees in a patent dispute over anti-tumor drug Abraxane, telling a Massachusetts federal court there was nothing frivolous about its case.
2 other articles on this case.
View all »